Treatment: Radiation Therapy
Treatment: Radiation Therapy
复制标题
DOI：
10.1007/978-3-319-40389-2_5
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Sampath, Sagus
中科院分区：
文献类型：
--
作者：
Sampath, Sagus
放射治疗（RT）是治疗肺癌各个阶段不可或缺的一部分。立体定向消融放射治疗（SABR）已成为I-II期医学上无法手术的疾病患者的标准治疗选择。IIIA-IIIB期疾病通常采用明确的同步化疗放射治疗（CRT）。调强放射治疗（IMRT）能够提供更有效的放射剂量，同时极大地限制了对周围正常器官（包括肺、食道和心脏）的剂量。随着新的临床试验探索SABR与全身免疫疗法的结合，SABR在IV期患者的治疗中可能会发挥更大的作用。
Radiation therapy (RT) is an integral part of treating all stages of lung cancer. Stereotactic ablative radiation therapy (SABR) has emerged as a standard treatment option for stage I-II patients with medically inoperable disease. Stage IIIA-IIIB disease is typically managed with definitive concurrent chemo-radiotherapy (CRT). Intensity modulated radiation therapy (IMRT) has enabled delivery of more potent RT dose while greatly limiting dose to surrounding normal organs, including lung, esophagus, and heart. SABR may have an expanding role in the treatment of stage IV patients, with new clinical trials exploring its combination with systemic immuotherapies.